ArticleScientific reports2026
Development and validation of a stability-indicating high-performance liquid chromatography method for iomeprol.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
This study aimed to develop and validate a reliable reversed-phase high-performance liquid chromatography (RP-HPLC) method for the simultaneous separation and quantification of iomeprol and its related impurities in contrast agent injections. The method employed a Nanochrom ChromCore AQ C18 column with gradient elution using a mobile phase consisting of phosphate buffer and a mixture of water, acetonitrile, and 2-butanol. Through systematic optimization, the method effectively addressed the limitations of existing techniques, such as LC-MS/MS and online SPE-POPLC, including insufficient impurity resolution and high detection costs. Validated in accordance with ICH Q2(R1) guidelines, the method demonstrated excellent performance in all parameters: high specificity with baseline separation of all impurities and no interference from excipients; linearity over the range from LOQ to 200% (R² > 0.999); accuracy with recovery rates of 96%–101% (RSD < 3%); precision with RSD values below 2.0% for both repeatability and intermediate precision; and robustness under varied chromatographic conditions, with solutions remaining stable for up to 35 h. Forced degradation studies revealed that iomeprol is particularly susceptible to degradation under alkaline and photolytic conditions, highlighting the importance of pH control and light protection during formulation and storage. This RP-HPLC method provides a sensitive, accurate, precise, and robust analytical tool for quality control of iomeprol in both active pharmaceutical ingredients and finished products, offering significant technical support for enhancing drug quality and ensuring clinical medication safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.